Loading...

David B. Agus, MD

Title(s)Professor of Medicine and Biomedical Engineering
Phone+1 310 272 7640
vCardDownload vCard
    Other Positions
    Title(s)Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

    Title(s)Director, USC Center for Applied Molecular Medicine


    Collapse Biography 
    Collapse Awards and Honors
    American Cancer Society1996  - 2001Physician Research Award
    Sloan-Kettering Institute1996Clinical Scholar Award
    American Cancer Society1994Clinical Oncology Fellowship Award
    HealthNetwork Foundation2008Excellence Award
    Geoffrey Beene Foundation2009Rock Stars of Science™
    Biotech Humanitarian Award2009Selected Judge
    USC Association of Trojan Leagues2013Outstanding Service Award
    American College of Physicians2016Fellow
    Ellis Island Medal of Honor2017Medalist

    Collapse Overview 
    Collapse Overview
    Dr. David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the founding director of USC’s Lawrence J. Ellison Institute for Transformative Medicine.   Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs, and directs a National Cancer Institute Physical Sciences in Oncology Center at USC.  He is a medical oncologist and the co-founder of several personalized medicine companies. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare, serving in leadership roles at the World Economic Forum, among other prestigious organizations. Dr. Agus’ first book called “The End of Illness” was published in 2012 and is a New York Times #1 and international best seller and was the subject of a PBS series, and his most recent books “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are also New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital.

    Collapse Research 
    Collapse Research Activities and Funding
    (PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
    NIH/NCI R01CA180149Sep 5, 2013 - Jul 31, 2017
    Role: Principal Investigator
    UCLA SPORE in Prostate Cancer
    NIH/NCI P50CA092131Jul 1, 2001 - Aug 31, 2019
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Faculty Mentoring
    Collapse Twitter
    Collapse Featured Videos
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Patsch K, Matasci N, Soundararajan A, Diaz P, Agus DB, Ruderman D, Gross ME. Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Res Notes. 2019 May 15; 12(1):275. PMID: 31092276.
      View in: PubMed
    2. Truong C, Krawczyk N, Dejman M, Marshall-Shah S, Tormohlen K, Agus D, Bass J. Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. Addict Behav. 2019 Jun; 93:14-19. PMID: 30682677.
      View in: PubMed
    3. Rawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. NPJ Breast Cancer. 2018; 4:32. PMID: 30211313.
      View in: PubMed
    4. Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A. Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 11; 18(11):e653-e706. PMID: 29208398.
      View in: PubMed
    5. Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. PMID: 28826933.
      View in: PubMed
    6. Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes LD, Alvarez RM, Wood DM, Joo AY, Katz JE, Agus DB, Mallick P. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Mol Cancer Ther. 2017 08; 16(8):1645-1657. PMID: 28566434.
      View in: PubMed
    7. Fröbert O, Götberg M, Angerås O, Jonasson L, Erlinge D, Engstrøm T, Persson J, Jensen SE, Omerovic E, James SK, Lagerqvist B, Nilsson J, Kåregren A, Moer R, Yang C, Agus DB, Erglis A, Jensen LO, Jakobsen L, Christiansen EH, Pernow J. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J. 2017 Jul; 189:94-102. PMID: 28625387.
      View in: PubMed
    8. Agus DB, Gaudette É, Goldman DP, Messali A. The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016; 11(11):e0166103. PMID: 27902693.
      View in: PubMed
    9. Patsch K, Chiu CL, Engeln M, Agus DB, Mallick P, Mumenthaler SM, Ruderman D. Single cell dynamic phenotyping. Sci Rep. 2016 10 06; 6:34785. PMID: 27708391.
      View in: PubMed
    10. Juarez EF, Lau R, Friedman SH, Ghaffarizadeh A, Jonckheere E, Agus DB, Mumenthaler SM, Macklin P. Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. PMID: 27655224.
      View in: PubMed
    11. Garvey CM, Spiller E, Lindsay D, Chiang CT, Choi NC, Agus DB, Mallick P, Foo J, Mumenthaler SM. A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016 07 25; 6:29752. PMID: 27452732.
      View in: PubMed
    12. Jones JJ, Wilcox BE, Benz RW, Babbar N, Boragine G, Burrell T, Christie EB, Croner LJ, Cun P, Dillon R, Kairs SN, Kao A, Preston R, Schreckengaust SR, Skor H, Smith WF, You J, Hillis WD, Agus DB, Blume JE. A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016 06; 15(2):186-194.e13. PMID: 27237338.
      View in: PubMed
    13. Chiu CL, Patsch K, Cutrale F, Soundararajan A, Agus DB, Fraser SE, Ruderman D. Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016 Mar 03; 6:22435. PMID: 26936218; PMCID: PMC4776155.
    14. Davies PC, Agus DB. Stochasticity and determinism in cancer creation and progression. Converg Sci Phys Oncol. 2015 Dec; 1(2). PMID: 29170717.
      View in: PubMed
    15. Agus DB. THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW. Fortune. 2016 Jan 01; 173(1):90-3. PMID: 26875351.
      View in: PubMed
    16. Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. PMID: 26244007.
      View in: PubMed
    17. Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23; 385(9982):2118-9. PMID: 25957453.
      View in: PubMed
    18. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31. PMID: 25624429.
      View in: PubMed
    19. Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. PMID: 25556680.
      View in: PubMed
    20. Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. PMID: 24891013.
      View in: PubMed
    21. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. PMID: 24418642.
      View in: PubMed
    22. Goldman DP, Gupta C, Vasudeva E, Trakas K, Riley R, Lakdawalla D, Agus D, Sood N, Jena AB, Philipson TJ. The Value of Diagnostic Testing in Personalized Medicine. Forum Health Econ Policy. 2013 Sep 01; 16(2):S87-S99. PMID: 31419871.
      View in: PubMed
    23. Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. PMID: 23618955; PMCID: PMC3636513.
    24. Gordon MS, Mendelson DS, Gross M, Uttenreuther-Fischer M, Ould-Kaci M, Zhao Y, Stopfer P, Agus DB. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. PMID: 23242861.
      View in: PubMed
    25. Agus DB, Gell-Mann M. Perspective: Meeting of minds. Nature. 2012 Nov 22; 491(7425):S61. PMID: 23320291.
      View in: PubMed
    26. Agus DB. Reframe the health debate. Fortune. 2012 Oct 29; 166(7):22. PMID: 23156666.
      View in: PubMed
    27. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, Mallick P. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct; 30(10):918-20. PMID: 23051804.
      View in: PubMed
    28. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. PMID: 22911164.
      View in: PubMed
    29. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. PMID: 22422671.
      View in: PubMed
    30. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. PMID: 22411897.
      View in: PubMed
    31. Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79. PMID: 21995722.
      View in: PubMed
    32. Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. PMID: 22002543.
      View in: PubMed
    33. Fang Q, Kani K, Faca VM, Zhang W, Zhang Q, Jain A, Hanash S, Agus DB, McIntosh MW, Mallick P. Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. PMID: 21829587.
      View in: PubMed
    34. Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55. PMID: 21147910.
      View in: PubMed
    35. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, Agus D, Cooney K, Chen A, Smith DC, Hussain M. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. PMID: 21049281.
      View in: PubMed
    36. Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. PMID: 20564426.
      View in: PubMed
    37. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. PMID: 20581083.
      View in: PubMed
    38. Mink SR, Vashistha S, Zhang W, Hodge A, Agus DB, Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20. PMID: 20530582.
      View in: PubMed
    39. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, Tindell C, Agus DB. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 01; 70(5):1989-99. PMID: 20160029.
      View in: PubMed
    40. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S, Redkar S, Taverna P, Agus DB, Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. PMID: 19825806.
      View in: PubMed
    41. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. PMID: 18756584.
      View in: PubMed
    42. Bearer EL, Lowengrub JS, Frieboes HB, Chuang YL, Jin F, Wise SM, Ferrari M, Agus DB, Cristini V. Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501. PMID: 19366801.
      View in: PubMed
    43. Luethy R, Kessner DE, Katz JE, Maclean B, Grothe R, Kani K, Faça V, Pitteri S, Hanash S, Agus DB, Mallick P. Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. PMID: 18707148.
      View in: PubMed
    44. Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 01; 24(21):2534-6. PMID: 18606607.
      View in: PubMed
    45. Stephan D, Agus D, Nierenberg M, Silver E. Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. PMID: 18606304.
      View in: PubMed
    46. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39. PMID: 18213636; PMCID: PMC3681409.
    47. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul 27; 7:142. PMID: 17662137.
      View in: PubMed
    48. Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 01; 13(7):1979-86. PMID: 17404077.
      View in: PubMed
    49. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81. PMID: 17308272.
      View in: PubMed
    50. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. PMID: 17317831.
      View in: PubMed
    51. deVera IE, Katz JE, Agus DB. Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. PMID: 17147241.
      View in: PubMed
    52. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. PMID: 16536755.
      View in: PubMed
    53. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer. 2006 Jan 16; 94(1):85-92. PMID: 16306877.
      View in: PubMed
    54. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8. PMID: 16265675.
      View in: PubMed
    55. Katz JE, Mallick P, Agus DB. A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82. PMID: 16104895.
      View in: PubMed
    56. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB. Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. PMID: 16087880; PMCID: PMC1187965.
    57. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. PMID: 15699478.
      View in: PubMed
    58. Jain A, Agus DB. PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. PMID: 15467471.
      View in: PubMed
    59. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 01; 61(3):228-35. PMID: 15368474.
      View in: PubMed
    60. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB. Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. PMID: 15193259.
      View in: PubMed
    61. Shazer RL, Luthringer D, Agus DB, Gross ME. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. PMID: 16163211.
      View in: PubMed
    62. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. PMID: 14752077.
      View in: PubMed
    63. Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. PMID: 15052539.
      View in: PubMed
    64. Gross ME, Jo S, Agus DB. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. PMID: 16163160.
      View in: PubMed
    65. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. PMID: 12874026.
      View in: PubMed
    66. Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS. Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 06; 94(21):1641-7. PMID: 12419791.
      View in: PubMed
    67. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, Agus DB. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31. PMID: 12374693.
      View in: PubMed
    68. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37. PMID: 12204533.
      View in: PubMed
    69. Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. PMID: 12101412.
      View in: PubMed
    70. Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55. PMID: 11986232.
      View in: PubMed
    71. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93. PMID: 12006510.
      View in: PubMed
    72. Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, Choudhri TF, Kim LJ, Mocco J, Pinsky DJ, Fox WD, Israel RJ, Boyd TA, Golde DW, Connolly ES. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11720-4. PMID: 11573006.
      View in: PubMed
    73. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res. 2001 Sep; 7(9):2643-7. PMID: 11555574.
      View in: PubMed
    74. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279. PMID: 11395644.
      View in: PubMed
    75. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr; 7(4):962-70. PMID: 11309347.
      View in: PubMed
    76. Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX. A potential role for activated HER-2 in prostate cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):76-83; discussion 92-100. PMID: 11236032.
      View in: PubMed
    77. Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PMID: 11236029.
      View in: PubMed
    78. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000 Nov 01; 60(21):6134-41. PMID: 11085537.
      View in: PubMed
    79. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000 Sep 15; 60(18):5165-70. PMID: 11016644.
      View in: PubMed
    80. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000 May 01; 60(9):2317-22. PMID: 10811100.
      View in: PubMed
    81. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999 Dec; 17(12):3776-85. PMID: 10577849.
      View in: PubMed
    82. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999 Nov 03; 91(21):1869-76. PMID: 10547394.
      View in: PubMed
    83. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999 Oct 01; 59(19):4761-4. PMID: 10519379.
      View in: PubMed
    84. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999 Sep 15; 59(18):4555-8. PMID: 10493506.
      View in: PubMed
    85. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C, Scher HI. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res. 1998 Jul 15; 58(14):3009-14. PMID: 9679964.
      View in: PubMed
    86. Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG, Thalmann GN. Workgroup 2: human xenograft models of prostate cancer. Prostate. 1998 Jun 15; 36(1):56-8. PMID: 9650917.
      View in: PubMed
    87. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 1997 Dec 01; 100(11):2842-8. PMID: 9389750.
      View in: PubMed